ProfileGDS5678 / 1452653_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 90% 89% 86% 88% 93% 93% 92% 91% 90% 90% 90% 90% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9995489
GSM967853U87-EV human glioblastoma xenograft - Control 27.2532290
GSM967854U87-EV human glioblastoma xenograft - Control 37.1321589
GSM967855U87-EV human glioblastoma xenograft - Control 46.7868786
GSM967856U87-EV human glioblastoma xenograft - Control 56.9564488
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.6656793
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.6368793
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.5541192
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.462391
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2709290
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.2367790
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1987190
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.2330690
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2733290